Jerath, NameetShetty, Ganesh2007-12-052009-05-302007-12-052009-05-302007-12-05Jerath N, Shetty G. Redefining the management of pediatric tonsillopharyngitis with cefprozil. Indian Journal of Pediatrics. 2007 Dec; 74(12): 1105-8http://imsear.searo.who.int/handle/123456789/8091833 references.Tonsillopharyngitis is very common in children, with Group A Streptococci being the most common bacterial etiology. Effective antibacterial treatment is imperative due to risk of rheumatic fever. Cephalosporins have been used successfully for the treatment of Group A beta-hemolytic Streptococcal (GABHS) tonsillopharyngitis. Cefprozil is a novel broad-spectrum oral cephalosporin. Cefprozil is rapidly absorbed from the gastrointestinal tract with high bioavailability. The excellent penetration of cefprozil into tonsillar and adenoidal tissue corresponds well with the clinical outcome. The drug provides excellent coverage against both gram-negative and -positive bacteria that may cause pharyngitis/tonsillitis. The beta-lactamase stability of cefprozil appears to exceed that of other oral cephalosporins for important gram negative pathogens. In clinical trials, cefprozil appears to be at least as effective as commonly used comparison agents such as cefaclor and cefixime. Additionally, cefprozil is better tolerated than the latter, especially with regard to gastrointestinal adverse effects. Thus cefprozil can be considered a safe and reliable drug for the treatment of Streptococcal tonsillopharyngitis in children.engAcute DiseaseAnti-Bacterial Agents --administration & dosageCephalosporins --administration & dosageChildChild, PreschoolDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansInfantMalePharyngitis --drug therapyRandomized Controlled Trials as TopicSensitivity and SpecificityTonsillitis --drug therapyTreatment OutcomeJournal Article